Masamune Higashigawa

541 total citations
55 papers, 355 citations indexed

About

Masamune Higashigawa is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Masamune Higashigawa has authored 55 papers receiving a total of 355 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 15 papers in Oncology and 13 papers in Hematology. Recurrent topics in Masamune Higashigawa's work include Cancer therapeutics and mechanisms (11 papers), HIV/AIDS drug development and treatment (7 papers) and Acute Myeloid Leukemia Research (7 papers). Masamune Higashigawa is often cited by papers focused on Cancer therapeutics and mechanisms (11 papers), HIV/AIDS drug development and treatment (7 papers) and Acute Myeloid Leukemia Research (7 papers). Masamune Higashigawa collaborates with scholars based in Japan and United States. Masamune Higashigawa's co-authors include Minoru Sakurai, Hajime Kawasaki, Masaru Ido, Hiroki Hori, Kazuya Ooi, Yoshihiro Komada, Ayako Yoshino, Hitoshi Kamiya, Hiroshi Kuwabara and Yoshiyuki Kagawa and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and British Journal of Haematology.

In The Last Decade

Masamune Higashigawa

51 papers receiving 343 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Masamune Higashigawa Japan 11 136 97 66 62 58 55 355
J Baró Spain 11 45 0.3× 137 1.4× 75 1.1× 50 0.8× 107 1.8× 30 366
Brenda J. Kitchen United States 10 205 1.5× 185 1.9× 77 1.2× 46 0.7× 86 1.5× 11 513
Manon Queudeville Germany 10 97 0.7× 85 0.9× 42 0.6× 128 2.1× 135 2.3× 27 332
Evelyne D’Incan France 10 119 0.9× 311 3.2× 47 0.7× 77 1.2× 98 1.7× 23 410
Naoya Ochiai Japan 12 60 0.4× 149 1.5× 28 0.4× 23 0.4× 95 1.6× 21 303
T Sylwestrowicz United Kingdom 9 171 1.3× 86 0.9× 24 0.4× 56 0.9× 40 0.7× 16 369
Alexandra Salmon France 13 86 0.6× 129 1.3× 105 1.6× 31 0.5× 126 2.2× 23 446
Judith Landman France 10 64 0.5× 251 2.6× 151 2.3× 26 0.4× 52 0.9× 11 391
Lisandro Ribeiro Brazil 9 93 0.7× 105 1.1× 24 0.4× 43 0.7× 47 0.8× 23 265
Richard McMasters United States 7 89 0.7× 102 1.1× 27 0.4× 93 1.5× 92 1.6× 12 299

Countries citing papers authored by Masamune Higashigawa

Since Specialization
Citations

This map shows the geographic impact of Masamune Higashigawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masamune Higashigawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masamune Higashigawa more than expected).

Fields of papers citing papers by Masamune Higashigawa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masamune Higashigawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masamune Higashigawa. The network helps show where Masamune Higashigawa may publish in the future.

Co-authorship network of co-authors of Masamune Higashigawa

This figure shows the co-authorship network connecting the top 25 collaborators of Masamune Higashigawa. A scholar is included among the top collaborators of Masamune Higashigawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masamune Higashigawa. Masamune Higashigawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Higashigawa, Masamune, et al.. (2023). Combination of prednisolone and cyclosporine A as third-line therapy for refractory Kawasaki disease. Minerva Pediatrics. 75(5).
2.
Higashigawa, Masamune, et al.. (2022). <i>Edwardsiella tarda</i> is an Important Causative Agent of Maternal-Fetal Infections in Pregnant Women: a Case Report and Japanese Literature Review. Japanese Journal of Infectious Diseases. 76(1). 80–83. 1 indexed citations
3.
Higashigawa, Masamune, et al.. (2021). Effectiveness of self-financed rotavirus vaccination in Ise City, Japan. Human Vaccines & Immunotherapeutics. 17(12). 5650–5655. 1 indexed citations
4.
Higashigawa, Masamune, et al.. (2019). Combination of prednisolone and cyclosporin A as third-line therapy for refractory Kawasaki disease: a case study. Minerva Pediatrics. 75(5). 682–688. 2 indexed citations
5.
Hosoki, Koa, Mizuho Nagao, Kosei Iguchi, et al.. (2011). An 8-Year-Old Boy with Hypereosinophilic Syndrome. International Archives of Allergy and Immunology. 155(Suppl. 1). 117–122. 7 indexed citations
6.
Higashigawa, Masamune, et al.. (2011). Clinical Investigation of Nine Pediatric Japanese Spotted Fever Cases. Kansenshogaku zasshi. 85(6). 638–643. 4 indexed citations
7.
Yamamoto, Keiko, Shigeru Ohta, Etsuro Ito, et al.. (2002). Marginal Decrease in Mortality and Marked Increase in Incidence as a Result of Neuroblastoma Screening at 6 Months of Age: Cohort Study in Seven Prefectures in Japan. Journal of Clinical Oncology. 20(5). 1209–1214. 26 indexed citations
8.
Ooi, Kazuya, Masamune Higashigawa, Hajime Kawasaki, et al.. (2001). Plasma, Intestine and Tumor Levels of 5-Fluorouracil in Mice Bearing L1210 Ascites Tumor Following Oral Administration of 5-Fluorouracil, UFT (Mixed Compound of Tegafur and Uracil), Carmofur and 5'-Deoxy-5-fluorouridine.. Biological and Pharmaceutical Bulletin. 24(11). 1329–1331. 8 indexed citations
9.
Ooi, Kazuya, et al.. (1996). Effect of Etoposide on the Influx and Intracellular Accumulation of Cytosine Arabinoside in Human and Murine Leukemic Cell Lines and in Human Peripheral Leukemic Cells.. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 27(3). 569–573. 1 indexed citations
10.
Kawasaki, Hajime, et al.. (1996). Deoxycytidine kinase mRNA Levels in leukemia cells with competitive polymerase chain reaction assay. Leukemia Research. 20(8). 677–682. 10 indexed citations
11.
Nakano, Takashi, Kenji Sugiyama, Masamune Higashigawa, et al.. (1996). Clinical features of measles in immunocompromised children. Pediatrics International. 38(3). 212–217. 29 indexed citations
12.
Higashigawa, Masamune, et al.. (1996). A child case of CD34+, CD33−, HLA-DR−, CD7+, CD56+ stem cell leukemia with thymic involvement. Leukemia Research. 20(11-12). 983–985. 9 indexed citations
13.
Ooi, Kazuya, et al.. (1996). Effect of Etoposide on Cell Cycle Progression in Ll210 Murine Ascites Tumor.. Japanese Journal of Hospital Pharmacy. 22(2). 142–144. 1 indexed citations
14.
Zhou, Yan, et al.. (1994). Apoptotic Cell Death Induced by Anti-IgM Antibody and Phorbol Esters Is Inhibited by Interleukin-4 in Human B Lymphoma Cell Line MBC-1. Cellular Immunology. 159(2). 280–293. 11 indexed citations
15.
Kagawa, Yoshiyuki, et al.. (1993). Effects of 5-Fluorouracil and a Combination of Tegafur and Uracil (UFT) on Nucleotide Metabolism in L1210 Ascites Tumor. Cancer Investigation. 11(5). 530–533. 4 indexed citations
16.
Kawasaki, Hajime, et al.. (1991). Intracellular dCTP/ARA-CTP Ratio and the Cytotoxic Effect of ARA-C. Cancer Investigation. 9(4). 409–413. 7 indexed citations
17.
Kawasaki, Hajime, et al.. (1990). Intracellular ribonucleotide pools of lymphoblastic leukemic cells in untreated and relapsed all children. Medical and Pediatric Oncology. 18(2). 131–135. 1 indexed citations
18.
19.
Hori, Hiroki, Masamune Higashigawa, Hajime Kawasaki, et al.. (1989). Synergistic Interaction between Etoposide and 1-β-D-Arabinofuranosylcytosine. Advances in experimental medicine and biology. 253B. 355–362. 2 indexed citations
20.
Higashigawa, Masamune, Hajime Kawasaki, Hitoshi Kamiya, et al.. (1988). Sequence-dependent antitumor effect of VP-16 and 1-β-d-arabinofuranosylcytosine in L1210 ascites tumor. European Journal of Cancer and Clinical Oncology. 24(12). 1823–1828. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J Baró Breakdown of academic impact, for papers by Brenda J. Kitchen Breakdown of academic impact, for papers by Manon Queudeville Breakdown of academic impact, for papers by Evelyne D’Incan Breakdown of academic impact, for papers by Naoya Ochiai Breakdown of academic impact, for papers by T Sylwestrowicz Breakdown of academic impact, for papers by Alexandra Salmon Breakdown of academic impact, for papers by Judith Landman Breakdown of academic impact, for papers by Lisandro Ribeiro Breakdown of academic impact, for papers by Richard McMasters
Rankless by CCL
2026